Products for Research Use Only
RegisterLogin

Saroglitazar

CAT: 0804-HY-19937-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19937-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
CAS Number
495399-09-2
UNSPSC
12352005
Hazard Statement
H302, H317
Target
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/Saroglitazar.html
Purity
99.85
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
OC([C@@H](OCC)CC1=CC=C(OCCN2C(C)=CC=C2C3=CC=C(SC)C=C3)C=C1)=O
Molecular Formula
C25H29NO4S
Molecular Weight
439.57
Precautions
H302, H317
References & Citations
[1]Jain MR, et al. Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect. 2015 Jun;3 (3) :e00136.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 4
Isoform
PPARα; PPARγ
Citation 01
Acta Pharm Sin B. 2025 Sep 19.|Ann Med. 2025 Dec;57 (1) :2497112.|Cell Biol Toxicol. 2021 Apr;37 (2) :293-311.|iScience. 2025 Apr 3;28 (5) :112344.|Medicina (Kaunas) . 2025 Jun 26;61 (7) :1157.|Patent. US20190388398A1.|Sci Adv. 2025 Sep 26;11 (39) :eads3731.|SSRN. 2024 May 30.|BMC Complement Med Ther. 2021 Apr 10;21 (1) :118.|Patent. US20210275504A1.

Alternative Products

CatalogName
BA4432-1Saroglitazar
GTR19204854-01Saroglitazar Magnesium
GTR19153896-01Saroglitazar (Magnesium)
A20636-100Saroglitazar 100mg

Popular Products